Please Scroll Down to See Forums Below 
The following study was conducted using Trans-D Tropin
ACCELERATED AND EFFICACIOUS RESULTS USING VARIABLE
SOMATOTROPH AND HYPOTHALAMOTROPH SPECIFIC POLY-PEPTIDE COMBINANTS UTILIZING A TRANS-DERMAL DELIVERY MECHANISM (TD-GHRH-A) AS AN
ALTERNATIVE TO RECOMBINANT HUMAN GROWTH HORMONE INJECTION THERAPY
Rashid A. Buttar, DO, FAAPM, FACAM
Dean C. Viktora, PhD
Michael E. Quinn, EMT-P
Abstract
Objective A patient outcome based study was conducted to investigate the possible efficacy of certain somatotroph and hypothalamotroph specific poly-peptide combinants which appear to emulate the action of GHRH resulting in a highly efficacious release of endogenous GH.
Background Although the GH injections and secretagogues do offer many benefits for the limitations of aging, the need for a safer and more effective modality of therapy has long been warranted.
Methods Of the 35 patients that were started on the study, 30 completed the full study. Groups were divided into sedentary and athletic groups. A total of 22 subjective criteria were monitored including: sense of well being, overall energy, mental clarity, emotional stability, memory improvement, mood improvement, skin thickness, skin elasticity, wrinkle disappearance, new hair growth, skin texture, healing of old injuries, healing of overall injuries, range of motion, incidence of illness, body contour change, facial contour change, sexual frequency, sexual stamina, libido, quality of erection/arousal, and change in nocturia. Objective criteria measured were muscle strength, overall energy, exercise endurance and quality of sleep. Laboratory data consisting of pre- and post- treatment IGF-1 levels and base line chemistries were also obtained. Changes were recorded by a self-assessment methodology utilizing a scale of -5 to +5 with 0 as base line. This accepted modality of evaluation with previous precedent having been set was chosen for this patient outcome based study.
Results Within the first week, changes experienced were overwhelmingly positive. Improvements were reported of 282.98% in the female subjects and 352.38% in male subjects. Muscle strength increased by 81.0%. Endurance increased by 60.0%. Quality of sleep improved by 92.6%. Overall energy increased by 71.4%. Total mean improvement of all 4 objective criteria increased by 76.6%. Interestingly, the 3 week post study IGF-1 levels dropped 20.39% within both athletic and sedentary study groups with a 27.16% drop in IGF-1 levels in the female patients and a 14.61% drop in IGF-1 levels in the male patient population.
Conclusions Efficacy based upon subjective criteria was far beyond expectation. Objectively measured increases in muscular strength conclusively show this TD-GHRH-A (trans-dermal GHRH analog) to be clinically superior for resistance training as compared to hGH injections. Simplicity of trans-dermal administration also appears to lead to a greater level of patient compliance. Substantial improvements in all criteria are further validation of this TD-GHRH-A (brand name Trans-D Tropin) as not only an effective alternative to hGH injections but perhaps a replacement of the more costly, potentially dangerous and less compliant injection treatments. The lack of correlation between clinical improvement and increasing IGF-1 levels also warrants re-evaluation of our currently accepted understanding of IGF-1. These results strongly warrant further clinical research of this TD-GHRH-A.
Accepted for Publication by The Journal of Integrative Medicine
ACCELERATED AND EFFICACIOUS RESULTS USING VARIABLE
SOMATOTROPH AND HYPOTHALAMOTROPH SPECIFIC POLY-PEPTIDE COMBINANTS UTILIZING A TRANS-DERMAL DELIVERY MECHANISM (TD-GHRH-A) AS AN
ALTERNATIVE TO RECOMBINANT HUMAN GROWTH HORMONE INJECTION THERAPY
Rashid A. Buttar, DO, FAAPM, FACAM
Dean C. Viktora, PhD
Michael E. Quinn, EMT-P
Abstract
Objective A patient outcome based study was conducted to investigate the possible efficacy of certain somatotroph and hypothalamotroph specific poly-peptide combinants which appear to emulate the action of GHRH resulting in a highly efficacious release of endogenous GH.
Background Although the GH injections and secretagogues do offer many benefits for the limitations of aging, the need for a safer and more effective modality of therapy has long been warranted.
Methods Of the 35 patients that were started on the study, 30 completed the full study. Groups were divided into sedentary and athletic groups. A total of 22 subjective criteria were monitored including: sense of well being, overall energy, mental clarity, emotional stability, memory improvement, mood improvement, skin thickness, skin elasticity, wrinkle disappearance, new hair growth, skin texture, healing of old injuries, healing of overall injuries, range of motion, incidence of illness, body contour change, facial contour change, sexual frequency, sexual stamina, libido, quality of erection/arousal, and change in nocturia. Objective criteria measured were muscle strength, overall energy, exercise endurance and quality of sleep. Laboratory data consisting of pre- and post- treatment IGF-1 levels and base line chemistries were also obtained. Changes were recorded by a self-assessment methodology utilizing a scale of -5 to +5 with 0 as base line. This accepted modality of evaluation with previous precedent having been set was chosen for this patient outcome based study.
Results Within the first week, changes experienced were overwhelmingly positive. Improvements were reported of 282.98% in the female subjects and 352.38% in male subjects. Muscle strength increased by 81.0%. Endurance increased by 60.0%. Quality of sleep improved by 92.6%. Overall energy increased by 71.4%. Total mean improvement of all 4 objective criteria increased by 76.6%. Interestingly, the 3 week post study IGF-1 levels dropped 20.39% within both athletic and sedentary study groups with a 27.16% drop in IGF-1 levels in the female patients and a 14.61% drop in IGF-1 levels in the male patient population.
Conclusions Efficacy based upon subjective criteria was far beyond expectation. Objectively measured increases in muscular strength conclusively show this TD-GHRH-A (trans-dermal GHRH analog) to be clinically superior for resistance training as compared to hGH injections. Simplicity of trans-dermal administration also appears to lead to a greater level of patient compliance. Substantial improvements in all criteria are further validation of this TD-GHRH-A (brand name Trans-D Tropin) as not only an effective alternative to hGH injections but perhaps a replacement of the more costly, potentially dangerous and less compliant injection treatments. The lack of correlation between clinical improvement and increasing IGF-1 levels also warrants re-evaluation of our currently accepted understanding of IGF-1. These results strongly warrant further clinical research of this TD-GHRH-A.
Accepted for Publication by The Journal of Integrative Medicine
